Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03252587 · ClinicalTrials.gov registry record · Phase 2
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 363
- Enrollment target
NCT03252587 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 363 participants.
The verdict
NCT03252587, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 363 participants
- Enrollment target
Study Summary
This study will investigate BMS-986165 to assess its effects in participants with systemic lupus erythematosus (SLE).
Interventions
- OTHER Placebo
- DRUG BMS-986165
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2021-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03252587
The ClinicalTrials.gov registry entry for NCT03252587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03252587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03252587 about?
NCT03252587 is a clinical study titled "An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus". This study will investigate BMS-986165 to assess its effects in participants with systemic lupus erythematosus (SLE).
What is the current status of trial NCT03252587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 363 participants. The study started on 2017-09-21. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT03252587?
The interventions under investigation include: Placebo (OTHER), BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT03252587?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.